WALTHAM, MA – Repligen Corporation (NASDAQ:RGEN) today

announced the launch of its new larger-scale OPUS™ brand chromatography columns used in the

manufacture of biopharmaceuticals. The OPUS™ (Open Platform User Specified) line extension is

being introduced in response to rising market demand for disposable technologies in

biopharmaceutical manufacturing. Such technologies are revolutionizing biomanufacturing by

enabling increased facility flexibility and operating efficiencies. The new OPUS™ chromatography

columns are now commercially available to biopharmaceutical manufacturers and developers

worldwide.

OPUS™ pre-packed, single-use plastic chromatography columns are suitable for multi-cycle

purification of biologics such as monoclonal antibodies, proteins and vaccines. The OPUS™ product

line is unique in providing customers with an open platform to accommodate an unprecedented range

of options in chromatography media, column sizes and bed heights. The scalability and immediate

“plug-and-play” usability of OPUS™ columns increases facility flexibility and can improve the speed

of process development and reduce the cost of biopharmaceutical manufacturing by decreasing the

set-up, cleaning and validation times associated with traditional purification technologies.

The OPUS™ line extension broadens the utility of OPUS™ columns to the production of a wider

range of clinical stage biologics and niche commercial products such as orphan biologics. The

Company estimates the total chromatography market for clinical stage biologics to be approximately

$100 million.

“We are pleased to introduce our larger-scale OPUS™ columns to the biomanufacturing market. As

with all of the chromatography products in the OPUS™ line, these new columns are uniquely

customizable, being pre-packed with media of our customers’ choosing,” said Walter C. Herlihy,

Ph.D., President and Chief Executive Officer of Repligen Corporation. “We are encouraged by the

early response to the new OPUS™ products from our current customers, as well as feedback from a

number of potential new customers who have been seeking process scale single-use chromatography

solutions.”

Repligen acquired the initial OPUS™ technology in March 2010 as part of the Company’s ongoing

commitment to leverage its core competency in bioprocessing into a broader purification product offering to the pharmaceutical industry. The Company’s bioprocessing business now sells 16 products

including:

1) all five forms of Protein A (native and recombinant), an essential component for the

manufacture of most therapeutic monoclonal antibodies on the market and in development;

2) four growth factor products used to increase productivity in cell culture; and,

3) seven chromatography products used to purify and analyze biologic drugs.

OPUS™ chromatography columns are now available and can be ordered through the Repligen’s

bioprocessing website: https://tinyurl.com/OPUS-Columns. We will be launching the new OPUS™

columns and exhibiting the Company’s current line of bioprocessing products at the following

upcoming events:

• 4thAnnual Disposable Solutions for Biomanufacturing, Feb. 27-29, 2012, Brussels, Belgium

• IBC Biopharmaceutical Development & Production Week, Feb. 29-March 2, 2012, San Diego

• BioProcess International Europe, April 18-19, 2012, Prague, Czech Republic

About Repligen Corporation

Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic

drugs. Repligen also applies its expertise in biologic product development to SecreFlo™, a synthetic

hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic

diseases. In addition, the company has two central nervous system (CNS) rare disease programs in

Phase 1 clinical trials. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1,

Suite 100, Waltham, MA 02453.